Walleye Capital
BCAX

Walleye Capital’s Bicara Therapeutics BCAX Stock Holding History

Walleye Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
353,226
+245,218
+227% +$5.47M 0.04% 457
2026
Q1 		$2.15M Buy
+108,008
New +$1.86M 0.01% 1412
2025
Q3 		– Sell
-24,308
Closed -$226K – 5263
2025
Q2 		$226K Buy
+24,308
New +$290K ﹤0.01% 3265
2024
Q4 		– Sell
-31,780
Closed -$809K – 5727
2024
Q3 		$809K Buy
+31,780
New +$810K ﹤0.01% 2854

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Walleye Capital's BCAX Position: Q2 2026 in Review

Walleye Capital increased its Bicara Therapeutics (BCAX) stake by 227% in Q2 2026, buying an estimated $5.47M and bringing the position to 353,226 shares worth $10.5M. The position accounts for 0.04% of the portfolio, ranked #457.

Walleye Capital first reported a position in BCAX in Q3 2024 and has held it in 4 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Walleye Capital held 353,226 shares of Bicara Therapeutics worth $10.5M as of Q2 2026.
  • Walleye Capital bought 245,218 Bicara Therapeutics shares in Q2 2026, an estimated $5.47M.
  • Bicara Therapeutics made up 0.04% of Walleye Capital's portfolio in Q2 2026, its #457 holding.
  • Walleye Capital first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.